Molukat 4mg DHG medicine prevents and treats mild to medium level asthma (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications DHG

Uses

indications

Molukat 4 drug indicated in the following cases:

Additional therapy in asthma treatment in patients from 2-5 years old with mild to moderate asthma, uncontrolled by inhaled corticosteroids and in patients who do not control asthma attacks when using short -effects of condderetes to control asthma attacks when necessary. Oral corticosteroids, and in patients inhaled corticosteroidal tolerances. age and older).

Cysteinyl Leukotrien (LTC4, LTD4, LTE4) are important mediators, attached to cysteinyl leukotrien receptors (CYSLT). CYSLT1 is found in his airway. In asthma, the intermediate effects of Leukotrien include a number of airway effects, such as bronchospasm, affecting the secretion of mucus, capillary permeability and the addition of eosin blood cells. In allergic rhinitis, CYSLT is secreted from the nasal mucosa after exposure to the antigen and is related to the symptoms of allergic rhinitis. Cyslt in the nose will increase the airway resistance and congestion symptoms.

Montelukast is an anti -inflammatory substance. Montelukast strongly inhibits the physiological effects of LTC4, LTD4, and LTE4 at CYSLT1, so it reduces the symptoms of asthma and allergic rhinitis. In Hen Hen, Montelukast causes bronchiectasis for 2 hours after drinking.

Dynamic pharmacokinetics

After drinking, Montelukast absorbs quickly and almost completely. Food does not have a great influence in clinical use when taking long -term drugs. With 4 mg chewing tablets, CMAX concentration reaches 2 hours after taken for children 2-5 years old, taking medicine when hungry. Montelukast attaches more than 99% to plasma proteins. The drug is very strong. Montelukast and the metabolites of the drug are almost completely excreted. Montelukast's semi -discharged duration of plasma is 2.7 - 5.5 hours in healthy young people.

Before taking Molukat 4mg DHG medicine prevents and treats mild to medium level asthma (3 blisters x 10 tablets)

How to use

Molukat 4 medicine can chew or take the tablet with a moderate amount of water.

Dosage

Children 2 - 5 years old: Every day a chewing tablet 4 mg.

To treat asthma, need to use in the evening. With allergic rhinitis, the time to use the drug depends on the needs of each object. For patients with both asthma and allergic rhinitis, should be used a dose every day, in the evening.

If used with food, Montelukast should be used 1 hour or 2 hours after meals.

General recommendation:

Montelukast's treatment effect is based on asthma test parameters that will be achieved in a day. Patients should be advised to continue using Montelukast, although asthma attacks have been controlled, as well as in periods of severe asthma.

No need to adjust the dose for children in each age group, each gender, for the elderly, people with kidney failure, mild and medium liver failure. There is no drug used for patients with severe liver failure.

Treatment related to other asthma drugs:

Montelukast can be used in combination with patients who are following other treatments. Reduce the dose of combined drugs:

Bronchodilators: Montelukast can be added to the treatment regime for people who have not fully controlled just by bronchodilators. When there is a clinical evidence, usually after the first dose, bronchodilator can be reduced if tolerated.

Inhaled corticosteroids: Together with Montelukast, it has more treatment benefits for patients who are using inhaled corticosteroids. Corticosteroid dose can be reduced if tolerated. However, the dose of corticosteroids must gradually decrease under the supervision of the doctor. Do not suddenly replace corticosteroid inhalation with Montelukast.

or as directed by the physician.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What do

do when overdose? In most overdose reports, no harmful reactions. The most common reactions when overdose include drowsiness, abdominal pain, thirst, headache, vomiting and agitation. It is unclear whether Montelukast can split through the peritoneal or dialysis.

In an emergency, call the 115 emergency center immediately or go to the nearest local health station.

What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

The frequency of other side effects after bringing the drug to the market has not been recorded according to the frequency and organ system.

Very common (ADR ≥ 1/10)

Infection: Upper respiratory infection.

Common (1/100 ≤ ADR Digestive: diarrhea, nausea, vomiting.

The immune system: Hypersensitivity reaction. Pepper.

Blood and lymphatic system: Increasing bleeding trend.

The immune system: Eosin leukemia. Form.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

contraindicated

Molukat 4 drugs contraindicated in the following cases:

Hypersensitivity to any ingredients of the drug.

Caution when using

has not been valid when taking Montelukast in the treatment of acute asthma attacks, so Montelukast should not be used to treat acute asthma attacks.

may have to reduce the dose of inhaled corticosteroids with a doctor's supervision, but not to suddenly replace oral corticosteroids or inhales with Montelukast.

There has been a report on mental - mental effects in patients using Montelukast. Doctors should discuss these adverse effects with patients and/ or patients care. Should guide patients and/ or caregivers to notify the doctor if these effects occur.

When reducing the dose of corticosteroids using systemic sugar in patients using other anti-asthma drugs, including Leukotrien receptor antagonists, they will lead to a few cases of the following cases: Eosin hyperps, rash, short breath, heart complications and/ or neurological disease sometimes diagnosed as churg-strauss syndrome is the systemic vasculitis with EOSIN hypercertia. Although the cause of cause and effect has not been identified with Leukotrien receptor antagonists, caution and clinical monitoring should be closely monitored when reducing the body corticosteroid dosage in patients using Montelukast.

The drug contains aspartam, a source of phenylalanin. Patients with phenylceton - urinary should not use this drug.

The effect of the drug on driving and operating machinery

There is no basis to prove that the drug affects the ability to drive and operate machinery.

Using drugs for women during pregnancy and lactation

There has been no study on the use of Montelukast in pregnant people. Only for pregnant women when necessary and as directed by the doctor.

It is unclear whether the drug is excreted through breast milk, so be careful when used during breastfeeding.

Medicinal interaction

can be used Montelukast with other commonly used drugs in preventive and chronic treatment of asthma and allergic rhinitis treatment. In drug interactive studies, the recommended dose in Montelukast's treatment does not significantly affect the pharmacokinetics of the following drugs: Theophyllin, Prednisolon, Ethinyl Estradiol/Norethindrone 35/1), Terfenadin, Digoxin and Warfarin.

Montelukast's area under the curve (AUC) decreases by about 40% in people with phenobarbital, but there is no need to adjust the dose of Montelukast. Montelukast is metabolized by CYP 3A4, so it is necessary to be cautious, especially in children when using Montelukast with CYP 3A4 induction drugs such as phenytoin, phenobarbital and rifampicin.

Invitro studies show that Montelukast is a CYP 2C8 inhibitor. However, data from drug interactive studies with each other clinically by Montelukast and Rosiglitazon (is the substrate that represents drugs metabolized mainly by CYP 2C8) shows that Montelukast does not inhibit CYP 2C8 Invivo. Therefore, Montelukast does not change the metabolic process mainly through this enzyme (such as Paclitaxel, Rosiglitazon and Repaglinid).

Storage

In a dry place, the temperature does not exceed 300C, avoiding light.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.